Science & Research

Do dogs react differently to CBD oil than people do? How do pet owners know what methods and doses for CBD oils are safe for their four-legged friends? Explore more about the benefits and side effects of CBD oil for dogs in this article.

A recently published study, which spanned 12 years, suggests that people who experience depression may be twice as likely to consume cannabis.

A recent study from the Centre for Addiction and Mental Health in Toronto has debunked a myth that cannabis can influence drivers up to 24 and even 48 hours after consumption.

Canadian cannabis producer Atlas Biotechnologies has awarded a $300,000 grant to University of Alberta researchers for the investigation of cannabis as a potential therapy for multiple sclerosis (MS), Alzheimer’s disease, and Huntington’s disease.

Researchers at Washington State University have demonstrated strong economic disparities in the neighborhood distribution of cannabis businesses in a recent study.

A self-reported cannabis consumer study from Washington State University suggests that inhaled cannabis products reduce the severity of headaches and migraines by 49.6 percent and 47.3 percent, respectively.

A California study is offering $20 gift cards to cannabis consumers in exchange for anonymous information about how much cannabis they use, which will help in determining safe pesticide levels for cannabis crops.

The FDA has approved a human trials study by the Yale School of Medicine and CT Pharma investigating the effectiveness of cannabis-based medicines; it’s the first cannabis study on human subjects to be approved by the FDA.

The Centers for Disease Control (CDC) announced a breakthrough on Friday in its investigation into the ongoing vape crisis, singling out vitamin E acetate as the likely culprit behind the spate of hospitalizations and deaths.

A recent study published in the Journal of Psychopharmacology suggests that medical cannabis could significantly reduce PTSD symptoms such as severe depression and suicidal states.

A recent study investigating social responses to the words “cannabis” and “marijuana” found that word choice does not influence the public’s perception of the plant.

A new study by the University of Washington suggests that parents’ cannabis use, past or present, may be linked to their children’s substance abuse tendencies and overall health.

Colorado cannabis company Ebbu has been accused of violating Colorado investment laws by failing to properly disclose investor identities in its early fundraising rounds.

UC San Diego researchers are set to receive $3 million from the state, which will be split between five different CBD research projects.

Australia’s federal government is investing AU$3 million into researching the potential pain and side effect management options for cancer patients.

The USDA is awarding funds to research the transportation of hemp pollen in the wild; the study will use mathematical models and drone technology to monitor hemp’s pollen paths.

Scientists have created a bacteria solution that exudes industrial quantities of psilocybin, the psychedelic compound in “magic mushrooms” that is being studied as a potentially groundbreaking treatment for depression and other mental health afflictions.

Israeli cannabis researcher Dr. Raphael Mechoulam unveiled his latest research into the synthesizing of cannabinoid acids at the CannMed conference last week in Pasadena, California.

GW Pharmaceuticals is partnering up with New York’s Montefiore Medical Center to study CBDV, or cannabidivarin, as a treatment for autism.

Nine universities are receiving federal grants totaling $3 million to study the “potential pain-relieving properties” of minor cannabinoids and cannabis-sourced terpenes.

Yet another study has found that crime rates dropped near legal cannabis dispensaries in the years since cannabis was legalized in Colorado.

The UK’s Imperial College London is partnering with European medical cannabis company EMMAC for a study evaluating cannabis’ entourage effect as a pain relief option.

Researchers at Johns Hopkins University announced last week the formation of what is likely the world’s largest research facility dedicated to psilocybin and psychedelic medicinal research.

The DEA has announced an expansion of medical cannabis research options and a change in policy: hemp cultivators no longer need to register with the agency in light of the crop’s federal legalization.